Spots Global Cancer Trial Database for Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer

Official Title: Neoadjuvant Therapy With Herceptin and Taxol for Stage II/III Breast Cancer

Study ID: NCT00136539

Conditions

Breast Cancer

Interventions

Study Description

Brief Summary: The purpose of this study is to determine the effectiveness and safety of administering Herceptin in combination with Taxol (paclitaxel) in the treatment of women with HER2-positive, early stage breast cancer prior to surgery.

Detailed Description: Patients will receive Herceptin intravenously once weekly for 12 weeks, and Taxol intravenously every 3 weeks (week 1, week 4, week 7 and week 10). After 12 weeks of treatment, breast surgery will be performed (either a lumpectomy or a mastectomy). Once patients have recovered from the surgery, they will receive adriamycin and cytoxan every 3 weeks for 4 cycles (12 weeks total). After Herceptin and Taxol therapy, tumor assessment will be performed along with an echocardiogram and mammogram. At the time of surgery, re-assessment of the tumor will be done. Blood work will be performed on day one of each chemotherapy cycle.